FDA grants fund trials of treatments for brain cancer
Click Here to Manage Email Alerts
The FDA awarded 11 grants worth more than $25 million to fund clinical trials of medical products intended to treat patients with rare diseases.
Three of the grants will fund studies of products intended to treat brain cancers.
The grants — which provide funding over the next 4 years — are awarded through the Orphan Products Grants Program, a Congress-funded initiative that promotes clinical development of drugs, biologics, medical devices and medical foods for the treatment of rare conditions.
The grants support clinical studies of products that address unmet needs or offer the potential for highly significant improvements in diagnosis or treatment.
“Supporting the development and evaluation of new treatments for rare diseases is a critical part of the FDA’s mission,” Acting FDA Commissioner Janet Woodcock, MD, said in an agency-issued press release. “These grants are the latest examples of the FDA’s ongoing commitment to help meet the future and current health needs of those who suffer from a rare disease.”
The grants for brain cancer research are as follows:
- Eric M. Thompson, MD, associate professor of neurosurgery at Duke University, received $1.8 million to conduct a phase 2 study of peptide vaccine targeting cytomegalovirus antigen for treatment of newly diagnosed pediatric high-grade glioma and diffuse intrinsic pontine glioma, as well as recurrent medulloblastoma.
- Sani H. Kizilbash, MD, MPH, medical oncologist at Mayo Clinic in Rochester, Minnesota, received $1 million to conduct a phase 1 study of WSD0922-FU (Wayshine Biopharm) for the treatment of high-grade astrocytoma.
- Peter W. Stacpoole, MD, PhD, professor of medicine at University of Florida, received $2.5 million to conduct a phase 2A trial of dichloroacetate for treatment of glioblastoma multiforme.
Read more about
Click Here to Manage Email Alerts